To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Open Biosystems' Open Access™ RNAi Program Provides Peter MacCullum Cancer Centre with shRNAmir Technology
Open Biosystems, Inc. has announced that the Peter MacCullum Cancer Centre has joined its Open Access RNAi Program.
Through this program, the Peter MacCullum Cancer Centre has purchased Open Biosystems' whole genome human lentiviral shRNAmir library.
By participating in the Open Access RNAi Program, the hospital's community of 265 researchers is provided with the advanced RNAi technology targeting the entire human genome with multiple constructs per gene.
With this unique technology access model, program participants receive continual updates and upgrades as extensions of the libraries are released.
The Open Access RNAi Program also provides off-site backups and a partner specific technical support team.
This whole-genome resource enables all Peter MacCullum Cancer Centre investigators to target any gene in the human genome with improved knockdown efficiency and effectiveness.
"Our research division is one of the world's largest groups dedicated solely to cancer research, and we deeply value collaborative integration with local, national and international institutions," said Ricky Johnstone, principal investigator at the Peter MacCullum Cancer Centre.
"Open Biosystems supports our mission to develop the very best cancer treatment by granting us the most advanced shRNA technology at a fraction of the cost compared to the purchase of libraries as individuals."
"The libraries allow us to conduct RNAi-based studies to develop new technologies that will result in significant breakthroughs in biomedical research."
"World-renowned research organizations continue to experience and appreciate the value of shRNAmir technology through the Open Access RNAi Program, with participation in the program expanding throughout the globe," said Troy Moore, chief technical officer and co-founder of Open Biosystems.
"The Peter MacCullum Cancer Centre exemplifies the benefits that a whole genome RNAi resource provides to advancing scientific research and underscores our commitment to furthering all aspects of cancer research."
